Background/Objectives: Calcium hydroxylapatite (CaHA)-based dermal fillers are widely used in esthetic medicine due to their dual volumizing and biostimulatory properties. Despite their rising popularity, comparative clinical outcome data evaluating different CaHA fillers remain limited. This prospective, single-center, unblinded study aimed to establish the effectiveness of the CaHA filler Rennova^® Diamond Intense via comparison to the well-established CaHA filler Radiesse^® in terms of clinical performance, safety, and patient satisfaction. Methods: Thirty patients (28 female, 2 male) underwent a single-session bilateral injection of Rennova^® Diamond Intense (right side) and Radiesse^® (left side) in the lower and medial posterior facial regions. Outcomes evaluated at multiple time points included dermal thickness, skin elasticity, transepidermal water loss, patient-reported outcomes (S-GAIS), physician-assessed outcomes (P-GAIS), and adverse events. Results: Both fillers showed improvements across all parameters. Patient-reported S-GAIS indicated predominantly “improved” outcomes at days 60 and 120, whereas physician assessments (P-GAIS) predominantly indicated “very improved” results at day 120. Ultrasound revealed increases in dermal thickness for both fillers. Similarly, improvements in skin elasticity and decreases in transepidermal water loss were observed bilaterally. Mild, transient adverse events (pain, swelling, redness, bruising) resolved spontaneously within 30 days post injection. Conclusions: Rennova^® Diamond Intense effectively increases dermal thickness, improves skin elasticity, and reduces transepidermal water loss, achieving high patient and physician satisfaction. These findings underscore its safety, versatility, and efficacy for esthetic facial rejuvenation, warranting further long-term evaluation.

Both hyaluronic acid (HA) and calcium hydroxylapatite (CaHA) fillers have well-established indications in cosmetic medicine. Nevertheless, limited data are available on the effectiveness of combining CaHA and HA. The purpose of this report was to demonstrate the safety, tolerability, and clinical and ultrasonographic improvement of facial skin laxity using a blending technique that admixes HA and CaHA. Fifteen regular patients, including three men, between 25 and 71 years of age were reported. The participants were subjects who came regularly to the dermatologic office seeking a lifting effect without surgery. They were submitted to injection of an admixture of HA and CaHA and followed for 180 days. The clinical assessment consisted of photographic evaluation by two blind investigators, and a consensual subjective evaluation was performed by the physicians (PGAIS) using the five-point Global Aesthetic Improvement Scale. Dermal thickness was analyzed in jaw areas using high-frequency ultrasound. Subjects completed a satisfaction questionnaire with responses scored according to the five-point Global Aesthetic Improvement Scale (GAIS) to evaluate patient satisfaction. After 180 days of follow-up, clinical assessments by blinded physicians found that all patients improved. All the participants were highly satisfied with the results and reported exceptional improvement. Dermal thickness increased by 9.4% (8.2–10.8%), 14.0% (12.2–15.9%), and 18.8% (16.2–21.9%) at D90, D120, and D180, respectively, by ultrasonography. In conclusion, an injection technique using an admixture of CaHA and HA fillers was well tolerated, offering high satisfaction and long-lasting progressive benefits. The authors believe that this procedure optimizes the treatment time and results because HA promotes early volume restoration and CaHA stimulates long-term dermal remodeling through the synthesis of collagen and elastin.

Background: Injectable biostimulators, particularly Poly-L-Lactic Acid (PLLA), have significantly advanced aesthetic medicine by promoting collagen production for skin rejuvenation and volume restoration. This study investigates the efficacy and safety of hyperdiluted PLLA injections in the temples and neck, advocating for customized concentrations to enhance results and minimize risks Objective: To evaluate the clinical efficacy and safety profile of hyperdiluted PLLA injections in the neck and temple region. Materials and methods: All patients were treated with injections of hyperdiluted PLLA (Rennova Elleva®) in the neck and temple region. All patients underwent six-monthly clinical evaluations and kept self-reporting diaries to record any adverse effects during the first 30 days. Patient satisfaction was assessed using the Subject Global Aesthetic Improvement Scale (S-GAIS) on days 90 and 150 post-injection. Results: The study included 16 female patients with a mean age of 50.19 (11.3) years and a mean of BMI: 22.80 (2.2) kg/m². Eight patients (50%) reported mild to moderate injection site reactions, such as redness, pain, hardening, swelling, lumps, bruises, and skin discoloration, with most symptoms resolving within a few days. Clinically, no major adverse events were noted. On post-injection day 90, the average GAIS was 3.1 ± 0.86, indicating an overall “improved” aesthetic appearance, which improved to 2.5 ± 0.97 by day 150 (p=0.12). Conclusion: Hyperdiluted PLLA injections are a safe and effective treatment for facial rejuvenation in the temple and neck areas, offering sustained patient satisfaction and minimal adverse effects. The tailored injection technique, which accounts for unique anatomical characteristics, maximizes results and minimizes complications, highlighting the importance of customized treatment strategies in aesthetic medicine.

Lip augmentation using hyaluronic acid (HA) fillers has become one of the most popular non-surgical aesthetic procedures, yet it is not without risks, particularly vascular complications. This study explores a novel vertical injection technique for submucosal placement of HA fillers, designed to enhance safety and achieve natural-looking outcomes. Ten patients underwent lip augmentation using the proposed technique, which involved ultrasound-guided injections at predefined entry points to target intralabial compartments while minimizing the risk of labial artery injury. The results demonstrated high patient satisfaction, with significant improvements in lip volume and contour. The submucosal placement yielded subtle, natural results with fewer visible irregularities compared to superficial injections. No major complications, such as vascular occlusion, were observed, and minor side effects, including transient swelling and redness, resolved within 48 h. The use of ultrasound imaging allowed precise filler placement and reduced the risks associated with traditional horizontal injection paths parallel to the labial arteries. While the findings highlight the technique’s potential in terms of safety and efficacy, limitations include the small sample size, short-term follow-up, and the absence of a control group. Further studies with larger cohorts and comparative analyses are needed to validate long-term outcomes. This innovative approach underscores the importance of anatomical precision and advanced imaging technologies in enhancing safety and aesthetic outcomes in lip augmentation.